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Hereditary angio-oedema (HAE) is a life-threatening autosomal 
dominant condition caused by a deficiency in the C1-esterase 
inhibitor (C1-INH), a pivotal protein in the complement and 
fibrinolytic pathways.[1] The condition was first described over 100 
years ago,[2] yet little is known about it in sub-Saharan Africa, with 
only an isolated report of a case in a Zulu kindred having appeared 
in the literature.[3]
Over a period of 35 years, 60 cases of HAE have been identified 
between the Allergy Clinic at Groote Schuur Hospital, Cape Town, 
South Africa (SA), and the Allergy Diagnostic and Clinical Research 
Unit (ADCRU) at the University of Cape Town (UCT) Lung Institute. 
To our knowledge, this is the largest cohort of HAE patients on the 
African continent. This study describes a series of adult patients with 
HAE living in the Western Cape Province.
Objectives
To retrospectively analyse the adult cases of type 1 HAE identified in 
the Western Cape cohort.
Methods
We reviewed the clinical records of all cases of HAE that were 
diagnosed at ADCRU and the Groote Schuur Hospital Allergy 
Clinic. A total of 60 patient records were reviewed. After excluding 
17 cases (7 patients did not live in the Western Cape, and the rest 
were minors (aged <18 years) diagnosed as index cases), 43 cases 
were included in our analysis. In all these 43 patients, type 1 HAE 
was confirmed by laboratory tests including functional C1-INH 
activity assays when available and/or determination of antigenic 
levels of the C1-INH enzymes to patient serum. C4 levels were 
measured in each patient. These patients either presented as index 
cases or were diagnosed after a family member had been diagnosed 
with type 1 HAE.
The parameters reviewed were age, gender, age of diagnosis, 
duration of illness, distribution of angio-oedema, diagnostic tests, 
family history, identifiable triggers, average duration of attack, 
number of attacks per year and type of attack (Table 1). Treatment 
regimens utilised for each patient were also reviewed.
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Background. Hereditary angio-oedema (HAE) is an autosomal dominant condition caused by a deficiency in the C1-esterase inhibitor 
protein, resulting in increased bradykinin release. It presents clinically with recurrent attacks of angio-oedema, commonly affecting the 
limbs, face, upper airway and gastrointestinal tract. Little is known about this condition in sub-Saharan Africa.
Objectives. To analyse and report on the clinical presentation and treatment of patients with HAE in the Western Cape Province, South Africa.
Methods. A retrospective analysis was conducted on a series of 60 cases of HAE seen between 2010 and 2015 at the Allergy Diagnostic and 
Clinical Research Unit, University of Cape Town Lung Institute, and the Allergy Clinic at Groote Schuur Hospital, Cape Town. The findings 
in 43 cases of type 1 HAE are described. Parameters assessed included age, gender, age of diagnosis, duration of illness, family history, 
identifiable triggers, average duration of attack, number of attacks per year and type of attack.
Results. A total of 43 patients were included in this study. Of these, 65.1% (28/43) were female. The median age at diagnosis was 20 years 
(interquartile range (IQR) 10 - 27) and the median duration of illness 10.5 years (IQR 6 - 22). Of the patients, 62.8% (27/43), 32.6% (14/43) 
and 4.7% (2/43) were of mixed ancestry, white and black African, respectively; 51.2% (22/43) were index cases, with the remaining 48.8% 
(21/43) diagnoses via family member screening, 12 families making up the majority of the cohort. The mean (standard deviation) duration 
of an acute attack was 49 (25.8) hours, and 64.3% (27/42), 71.4% (30/42), 14.3% (6/42) and 88.1% (37/42) of patients experienced facial or 
upper airway, abdominal, external genitalia and limb attacks, respectively. Danazol for long-term prophylaxis was used in 21 patients, while 
C1-inhibitor concentrate (Berinert) was accessed for short-term prophylaxis in only four patients. Acute life-threating attacks were treated 
with fresh frozen plasma in 11 patients, and only four accessed icatibant. The mortality rate for the period 2010 - 2015 was 4.5% (2/43). The 
prevalence of HAE in the Western Cape was estimated to be 1:140 000.
Conclusions. HAE occurs in South Africans of all ethnicities, and life-threatening attacks occur in almost two-thirds of patients. Despite 
limited therapeutic options and very limited access to gold-standard therapies available in the developed world, our mortality rate is very 
low, with both the deaths related to inability to access emergency treatment rapidly.
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Ethical considerations
Ethics approval was obtained from the 
Stellen bosch University Human Research 
Ethics Committee (ref. no. S16/05/090) and 
the UCT Human Research Ethics Committee 
(ref. no. 462/2016). The study was conducted 
in accordance with the ethical principles set 
out in the Declaration of Helsinki (2013), 
and permission to study the patients was 
obtained from the medical superintendent 
of Groote Schuur and Tygerberg hospitals.
Patient confidentiality was maintained at 
all times by allocating a study number to 
each patient prior to removing identifiable 
personal information from patients’ files and 
collating them in a data collection sheet.
Results
Baseline data for the 43 patients reported 
in this study are set out in Table 1. Of 
the patients, 65.1% (28/43) were female. 
The median age at diagnosis was 20 years 
(interquartile range (IQR) 10 - 27) and the 
median duration of illness under care 10.5 
years (IQR 6 - 22) (n=42) (Fig. 1). Of the 
patient cohort, 62.8% (27/43) were of mixed 
ancestry, 32.6% (14/43) white and 4.7% 
(2/43) black African; patient ethnicities were 
self-reported during screening. The majority 
of the patients were index cases (51.2%, 
22/43), with the remaining 48.8% (21/43) 
diagnosed via family member screening. 
Overall, 12 families were screened for HAE 
in this cohort. No patient with type 2 HAE 
was identified. An example of a family tree 
showing Mendelian dominant inheritance 
is provided in Fig. 2. The mean (standard 
deviation) duration of an acute attack was 
49 (25.8) hours. The only missing basic 
clinical data were 2 patients without age at 
diagnosis, 2 without duration of illness, 1 
without anatomical distribution of oedema, 
3 without C4 levels and 4 without C1-INH 
levels; however, only 18 patients had data on 
the duration of acute attacks. The mortality 
rate for the period 2010 - 2015 was 4.5% 
(2/43). Just over half (53.0%, 23/43) of our 
patients were seen as private patients, the 
remaining 46.5% (20/43) being treated in 
the public healthcare sector. The distribution 
of attacks is shown in Fig. 3. There were no 
significant differences when analysing by 
ethnicity or gender.
Danazol for long-term prophylaxis was 
used in 48.8% of patients (21/43). Most 
patients were treated with doses between 
100 and 200 mg/d without significant 
side-effects (hypertension, dyslipidaemia, 
hirsutism, virilisation and hepatic disease) 
being detected at their 6-monthly follow-
up visits. Liver function tests were done at Ta
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each follow-up visit. Only four patients (9.3%) used C1-inhibitor 
concentrate (Berinert) as short-term prophylaxis during elective 
surgery. The majority (66.0%) were well controlled on danazol only. 
A total of 19 patients (44.2%) were treated for life-threatening attacks 
involving the airway or gastrointestinal tract. Two of these patients 
had stopped long-term danazol prophylaxis prior to their planned 
pregnancies. One patient received C1-inhibitor concentrate during 
an acute attack involving the upper airway, and responded rapidly 
with relief of symptoms after the infusion. Fresh frozen plasma (FFP) 
was used for acute attacks in 25.6% of patients (11/43), 8 in the public 
sector and 3 in the private sector. Icatibant was used to treat 9.3% of 
patients (4/43) for life-threatening attacks. Patients with laryngeal 
or abdominal attacks required admission to an intensive care unit 
(ICU) for treatment and observation for 3 - 5 days. These patients 
had an average of 11.75 life-threatening attacks per annum, despite 
being on maximal doses of danazol prophylaxis. The group treated 
with icatibant demonstrated rapid resolution of symptoms during 
an attack, with symptom relief starting as early as 20 minutes post 
injection and full resolution within 4 hours in the majority of cases. 
No adult patients in our case series were treated with tranexamic acid.
Most patients reported spontaneous onset of attacks, but others 
identified triggers that included minor limb trauma (e.g. tight shoes, 
gardening), emotional stress, menstruation, pregnancy and surgery.
The mortality rate for the period 2010 - 2015 was 4.7% (2/43). 
These two patients died as a result of laryngeal asphyxia. Both lived 
far from a hospital and died as a result of delayed access to a high-
care medical facility associated with transport delays. Another patient 
was admitted to an ICU and effectively treated with FFP four times 
during the study period for recurrent laryngeal angio-oedema, but 
did not require a tracheostomy.
Discussion
In 1888, Sir William Osler[2] was the first to describe a case of HAE, 
in a 24-year-old woman who presented with a lifelong history of 
recurrent episodes of painless, non-pruritic swellings of her body, 
each lasting between 1 and 4 days. These swellings affected various 
parts of her body – hands, fingers, kneecaps, elbows, face and lips – 
while some severe episodes presented with abdominal colic, nausea 
and vomiting. The attacks occurred spontaneously while she was 
feeling well, with no specific triggers identified. She reported that 
her mother suffered from similar symptoms. Osler then obtained a 
comprehensive family history, which revealed that these symptoms 
had been present in 28 family members in the preceding five 
generations, and noted that the patients experienced local swellings 
  22%  
                     >10 years
54%
24%
<5 years 5 - 10 years
Fig. 1. Duration of symptomatic hereditary angio-oedema prior to diagnosis.
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Male
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Fig. 2. An example of a hereditary angio-oedema family tree showing Mendelian dominant inheritance.
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in various parts of the body – face, hands, 
arms, legs, genitals, buttocks and throat. In 
one instance, death resulted from sudden 
oedema glottidis. The oedema was almost 
invariably associated with gastrointestinal 
disturbance, patients experiencing colic, 
nausea, vomiting and sometimes diarrhoea. 
Furthermore there was a marked hereditary 
disposition, the disease having affected 
members of the family in five generations.
It was not until 1963 that Donaldson 
and Evans[4] used immunoelectrophoresis to 
demonstrate in their own series of patients, 
with similar symptoms to those described 
by Osler, a deficiency of C1-INH. We 
know today that HAE is a rare autosomal 
dominant disorder caused by mutations of 
the C1-INH gene, resulting in a quantitative 
or qualitative deficiency of C1-INH. Over 
280 different C1-INH gene mutations have 
been identified so far, with a spontaneous 
mutation rate of 25%.[5,6]
HAE manifests clinically as recurrent 
episodes of non-pruritic oedema that can 
affect any part of the body, commonly 
involving structures of the upper airways, 
gastrointestinal tract, external genitalia and 
extremities, with up to a quarter of patients 
reporting local erythema prior to the onset 
of swelling. HAE can be distinguished from 
other forms of angio-oedema (IgE-mediated 
and physical forms) because attacks usually 
last longer (72 - 96 hours) and are not 
associated with pruritus and urticaria. 
Symptoms are not alleviated by steroids or 
antihistamines.[7] Central to the pathogenesis 
of type 1 HAE is a deficiency of C1-INH. 
This is a serine protease inhibitor belonging 
to the SERPING-1 family that serves as a 
major inhibitor of the complement system, 
proteases, kallikrein and Hageman factor 
(coagulation factor XIIa). Along with these 
functions, it also inhibits the formation of 
bradykinin from kininogen. A deficiency 
of C1-INH therefore causes an increase in 
kallikrein activity, resulting in excessive 
production of bradykinin.[5,6]
Bradykinin has been demonstrated to be 
the primary mediator responsible for the 
development of angio-oedema. It binds to the 
bradykinin β2 receptor on vascular endothelial 
cells, resulting in significant increases in 
vascular permeability. This increase in vascular 
permeability is thought to be due to its effect 
on endothelial tight junctions responsible for 
the regulation of water movement across the 
endothelial membrane.[6]
Worldwide incidences of HAE have 
been reported to range from 1:10 000 to 
1:150 000. [8] There is no gender or racial 
predominance for type 1 or type 2 HAE, 
but most reported cases of type 3 HAE have 
been in females.[9] Type 1 HAE accounts 
for 80% of cases globally. Type 2 and type 
3 HAE are rare conditions. In ~80% of 
reported cases of HAE-1 there is a positive 
family history, while 20% of new cases 
are attributed to de novo mutations of the 
SERPING1 protein.[9] There is considerable 
variation in interpersonal and intrapersonal 
severity of attacks, even among family 
members with the same gene defect. Most 
patients experience their first attack by the 
age of 15 years, with the mean age of onset 
of symptoms being 8 - 12 years.[10]
Typically the onset of oedema is described 
as crescendo in nature, developing over 
several hours, peaking at 12 - 24 hours 
and then resolving over the next 72 - 96 
hours. [11] Commonly identified triggers 
range from surgical procedures (dental 
procedures being the most common) to 
pregnancy, menstruation, minor trauma 
(sports, gardening, tight shoes), emotional 
stress, sepsis and drugs (oestrogen therapy 
and angiotensin-converting enzyme  inhibi-
tors). [11,12] Abdominal symptoms are domi-
nant in up to 25% of cases and manifest as 
intestinal colic due to intestinal wall and 
mesenteric oedema. Patients typically present 
with abdominal pain, nausea and vomiting.[11]
Life-threatening angio-oedema is the 
result of asphyxia due to swelling of the 
upper airway structures, usually the larynx, 
which accounts for the 15 - 30% mortality 
rate.[11] C4 levels are a useful screening test 
(especially in primary healthcare facilities), 
as low serum C4 levels are a consistent feature 
of untreated HAE. Patients who present with 
clinical features of angio-oedema and have 
normal levels of circulating C4 are unlikely 
to have HAE. The diagnosis of type 1 HAE is 
made by confirming low levels of antigenic 
C1-INH protein. However, if C1 esterase 
levels are normal or elevated (along with a low 
C4 level), functional C1-INH testing should 
be conducted to confirm type 2 HAE[6,8,11,12] 
(Table 2). Based on the data presented, the 
estimated prevalence of type 1 HAE in adults 
living in the Western Cape is 1:140 000. 
Possible explanations for the apparent low 
prevalence may be underdiagnosis of cases 
by attending doctors, or lack of referral of 
rural patients to a tertiary centre for further 
evaluation. A recently published study from 
Italy showed a prevalence of 1:64 935.[13] The 
median age of diagnosis in our case series 
was 20 years (IQR 10 - 27), while that in Italy 
was 25 years;[13] 67.4% (29/43) of our patients 
were female, which is not significantly 
different from the 53% female prevalence in 
the Italian study.[13] Most (60.5%, 26/43) of 
our patients were diagnosed as index cases, 
with no evident family history. The reported 
incidence of de novo mutations is 25%.[6]
Female patients with HAE are often more 
symptomatic than male patients. Oestrogens 
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have been implicated in worsening the course of the disease[14] and 
make treatment of female HAE patients challenging with regard to 
oral contraception, pregnancy, surgical procedures and menopause. 
The side-effects of long-term use of attenuated androgens (hirsutism, 
virilisation, hypertension and mood changes) negatively affect female 
patients more than males, making compliance more challenging. 
Androgens are contraindicated for use during pregnancy, especially 
in the first trimester. Pregnancy has a variable effect on the severity 
and frequency of attacks.
Very few patients in SA have access to plasma-derived human 
C1-inhibitor concentrate (Berinert), which is the globally recom-
mended form of prophylaxis for females during pregnancy.[7] The 
microsomal cytochrome p450 enzyme aromatase can convert 
androgens to oestrogens.[14] Danazol is therefore not recommended 
for use in patients who suffer from both HAE and breast cancer. 
There has been no documented decrease in fertility in females taking 
attenuated androgens for prophylaxis, but impaired fertility has been 
reported in males on this treatment.[14]
The standard prophylactic therapy for patients with HAE is 
danazol, an attenuated androgen. Prophylaxis with danazol is stopped 
in our patients who become pregnant (Table 3). One of our patients 
received a prophylactic C1-inhibitor concentrate intraoperatively 
for a caesarean section and reported no severe attacks during the 
peripartum period. She did, however, experience an increase in 
frequency of attacks during her pregnancy, while she was off danazol 
prophylaxis. Some of our patients have used C1-inhibitor concentrate 
as preoperative prophylaxis for major surgical procedures (e.g. hip 
replacement surgery).
HAE poses many challenges in SA. The major difficulty lies in 
not recognising the condition and its various clinical manifestations. 
Those who correctly clinically diagnose HAE are further challenged 
in the diagnostic work-up and treatment of these patients. Currently 
only C4 levels and C1-INH quantitative testing are available in SA 
through the National Health Laboratory Service and a few private 
laboratories. Functional C1-INH assays are not currently available for 
clinicians, and would be important in the diagnosis of type 2 HAE. 
We have not yet identified any patients with type 2 HAE. Functional 
assays can, however, be sent to European laboratories for evaluation. 
Serum specimens have to be shipped frozen, as the enzyme is heat 
labile. This is expensive and logistically difficult.
Access to novel therapies such as icatibant and C1-inhibitor 
concentrate, which are widely available in Europe and North 
America, are generally limited to only a few individuals in SA who 
have adequate medical insurance schemes. However, a state hospital 
has recently approved the use of C1-inhibitor concentrate for a young 
pregnant adult HAE patient. These medications are not yet registered 
in SA and have to be individually imported after obtaining permission 
via the Medicines Control Council (MCC). Furthermore, the cost of 
such medication has made it unaffordable for many patients. Most 
patients in the public health sector do not yet have access to these 
lifesaving treatments, recommended in global guidelines.[7]
In developed countries, ‘on-demand’ therapy,[15] whereby patients 
self-treat at home on the onset of symptoms and swellings, is 
available. SA patients, however, are dependent on clinicians initiating 
therapy with FFP once the disease has progressed. FFP is only given 
for abdominal or life-threatening upper airway attacks. However, 
there is limited documentation on the efficacy of FFP in the 
management of life-threatening angio-oedema in the literature.[16] 
This extended duration of treatment often results in longer recovery 
periods, more days off work and an overall negative economic 
impact. A 3-day admission to an ICU costs ~ZAR58 000, while 
an ‘on demand’ alternative, icatibant or C1-inhibitor concentrate, 
currently costs ~ZAR17 000 per treatment – with the added benefit 
of convenience and possibly enabling the patient to return to work 
the same day. C1-inhibitor concentrate can be used for acute attacks 
or for prophylaxis. It is safe and is also recommended for use in the 
paediatric age group.[17]
Many patients experience minor attacks involving the limbs. These 
are often self-limiting and the patient may not need FFP or expensive 
treatments such as C1-inhibitor concentrate or icatibant for every 
attack.
‘On-demand’ therapy with the selective bradykinin-β2-receptor 
antagonist icatibant is the gold standard of therapy for acute attacks 
in many developed countries. Patients are taught to recognise early 
symptoms of an attack and inject 30 mg subcutaneously, as published 
in both the FAST-1 and FAST-2 trials.[18]
Most patients respond well to the usual dose of danazol prophylaxis 
(200 mg/d). Some patients in our cohort were adequately controlled 
on 100 mg/d. Patients should be managed with the lowest possible 
dose that controls symptoms adequately. While 80.0% of the patients 
in our cohort observed over a 1-year period were well controlled 
on danazol prophylaxis alone, the remaining 20% were noted to 
have recurrent or severe attacks. Despite being on maximal doses 
of danazol, patients in this subgroup experienced an average of 11.5 
life-threatening attacks a year. Patients who have occasional minor 
attacks three or four times a year may be monitored without danazol 
prophylaxis. This is often the case with adolescent patients, who 
experience a few minor attacks per year.
Four patients in our cohort were treated with icatibant owing to 
their increased frequency of life-threatening attacks despite being 
compliant on maximal doses of danazol. Treatment with icatibant 
not only improved symptom alleviation (most reported improvement 
by 20 minutes post injection, and full resolution by 4 hours) but 
also decreased the financial burden of lost work days. Prior to 
treatment with icatibant, some of these patients had reported an 
estimated attack duration of 48 - 72 hours. Icatibant is also not yet 
Table 2. Diagnosis and pathogenesis of HAE
C1-INH concentration C1-INH function C4 Pathogenesis
HAE-1 Low Low Low Deficiency in amount of circulating C1-INH protein caused by a 
change in the genomic sequence of the C1-INH gene, resulting in 
impaired messenger RNA transcription or translation to a functional 
protein
HAE-2 Normal Low Low Caused by change in the genomic sequence of the C1-INH gene, 
resulting in a dysfunctional protein and an inability to form complexes 
with proteases
HAE-3 Normal Normal Normal Mutations in the factor XII gene
HAE = hereditary angio-oedema; C1-INH = C1-esterase inhibitor.
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licensed for use in SA unless imported on a named-patient basis 
(with approval from the MCC). On-demand therapy should be 
made available to all South Africans with HAE, as it can be self-
administered at home and does not require the patient to present to 
a healthcare facility. Icatibant is only indicated for acute attacks, and 
not for prophylaxis prior to undergoing surgical procedures.
While paediatric patients (aged <13 years) were not included for 
reporting in this study, they made up a significant proportion of 
our total cohort (10/60). Their cases will be the subject of a separate 
report. These patients are managed by paediatricians if they present 
as index cases, or are being closely monitored if they are diagnosed 
in the course of screening and remain asymptomatic. Prophylaxis is 
the cornerstone of preventive management in asymptomatic adult 
patients, but is not usually recommended in asymptomatic paediatric 
patients. Children can be treated with tranexamic acid (on a per 
kilogram dosage), but some children require danazol at low doses 
(per kilogram) to prevent recurrent attacks. C1-inhibitor concentrate 
is safe for use in children and should be made available to all age 
groups. Adolescent patients are managed in the adult clinics and are 
treated like adult cases.
In addition to increasing physician awareness of HAE, it would 
be beneficial if SA patients had support groups available locally. 
Some of our patients belong to international support groups (e.g. 
HAEi, the international umbrella organisation for the world’s 
HAE patient groups), but face challenges very different to their 
overseas counterparts, in particular access to the first-line treatments 
recommended in the International Global Consensus Guidelines 
for HAE.[7] Our challenges include obtaining approval for novel 
therapies via medical insurance schemes, arranging for emergency 
transportation to appropriate emergency rooms, and education of 
the medical profession and medical aid schemes on the efficacy of the 
new life-saving treatments. Transportation can pose a huge challenge 
in SA. One of our patients died as a result of laryngeal asphyxia while 
wating for an ambulance. Local HAE support groups will assist in 
making living with HAE in SA more manageable and in helping to 
improve doctor and public awareness.
All patients with a diagnosis of HAE should wear a Medic-Alert 
bracelet and have a written action plan for the treatment of acute 
attacks. They should also be notified to the South African Primary 
Immunodeficiency Register after providing the necessary consent.
Conclusion
This is the first large series of HAE to be reported on the African 
continent. HAE, rare in SA, is a life-threatening condition. Every 
clinician, particularly those working in emergency units, should have 
a standardised approach to angio-oedema and its management. HAE 
is not an IgE-mediated form of angio-oedema and therefore will 
not respond to corticosteroid or adrenaline therapy. While current 
practice in SA is in keeping with global guidelines for maintenance 
prophylaxis, treatment of HAE with novel therapies for acute attacks 
is limited to only a few select patients. With increased physician 
awareness, more patients with HAE will be correctly diagnosed. This 
will encourage global pharmaceutical companies to register novel 
therapies in SA. SA-based patient support groups are needed to assist 
patients living with HAE in this country and adequately address our 
unique challenges.
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